Edwards Lifesciences (EW) Tops Q3 EPS by 5c, Offers Q4 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts EW Hot Sheet
Price: $89.07 -1.13%
Revenue Growth %: +8.4%
Financial Fact:
Basic (in shares): 213.2M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +8.4%
Financial Fact:
Basic (in shares): 213.2M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Edwards Lifesciences (NYSE: EW) reported Q3 EPS of $1.07, $0.05 better than the analyst estimate of $1.02. Revenue for the quarter came in at $907 million versus the consensus estimate of $928.18 million.
GUIDANCE:
Edwards Lifesciences sees Q4 2018 EPS of $1.05-$1.20, versus the consensus of $1.21. Edwards Lifesciences sees Q4 2018 revenue of $950-1000 million, versus the consensus of $995.4 million.
For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Meta's capital-raising plans expose a major weakness in the AI boom
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
